"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

On Monday, Absci Corp (ABSI) stock saw a decline, ending the day at $3.81 which represents a decrease of $-0.19 or -4.75% from the prior close of $4. The stock opened at $3.88 and touched a low of ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Ballentine Partners LLC bought a new stake in Absci Co. (NASDAQ:ABSI – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 10,424 shares of the company’s stock, valued at ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

Absci management is scheduled to participate in a fireside chat on Wednesday, February 5 th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived ...

Fintel reports that on January 22, 2025, Needham initiated coverage of Absci (NasdaqGS:ABSI) with a Buy recommendation.

Absci Corp (ABSI) stock saw a decline, ending the day at $4 which represents a decrease of $-0.17 or -4.08% from the prior close of $4.17. The stock opened at $4.16 and touched a low of $3.92 during ...

Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...